Cargando…

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer

BACKGROUND: Several reports indicated that the expression of Yes-associated protein (YAP) was associated with multi-drug resistance. Acidic microenvironment increased by the overexpression of vacuolar-ATPase (V-ATPase) was also observed in tumor growth and drug resistance. We hypothesize that proton...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jing, Shi, Xiao-Yan, Li, Zhi-min, Pan, Xiao-hua, Li, Ze-Lian, Chen, Ying, Yan, Shi-Jie, Xiao, Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852784/ https://www.ncbi.nlm.nih.gov/pubmed/31718559 http://dx.doi.org/10.1186/s12860-019-0227-y

Ejemplares similares

Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway
por: Xiao, Lan, et al.
Publicado: (2021)

YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells
por: Xiao, Lan, et al.
Publicado: (2016)

Piperlongumine Induces Apoptosis and Synergizes with Cisplatin or Paclitaxel in Human Ovarian Cancer Cells
por: Gong, Li-Hua, et al.
Publicado: (2014)

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells
por: Tang, Xiao‐han, et al.
Publicado: (2019)

Octreotide-Paclitaxel Conjugate Reverses Paclitaxel Resistance by p38 Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in A2780/Taxol Human Ovarian Cancer Cells
por: Fan, Li-li, et al.
Publicado: (2020)

Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma
por: Li, Xiao, et al.
Publicado: (2015)

Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer
por: Song, Taejong, et al.
Publicado: (2017)

In vivo detection of dysregulated choline metabolism in paclitaxel-resistant ovarian cancers with proton magnetic resonance spectroscopy
por: Lu, Jing, et al.
Publicado: (2022)

Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma
por: Lee, Yoo-Young, et al.
Publicado: (2015)

Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice
por: Chen, Xi, et al.
Publicado: (2016)

Effects of postoperative use of proton pump inhibitors on gastrointestinal bleeding after endoscopic variceal treatment during hospitalization
por: Zhang, Yi-Yan, et al.
Publicado: (2023)

Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
por: Zhang, Xiao-Yu, et al.
Publicado: (2021)

Effect of YAP Inhibition on Human Leukemia HL-60 Cells
por: Chen, Min, et al.
Publicado: (2017)

Gastric Epithelial Cell Modality and Proton Pump Inhibitor
por: Masaoka, Tatsuhiro, et al.
Publicado: (2008)

Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by PDGFRB inhibitors
por: Yang, Dong, et al.
Publicado: (2023)

Co-Delivery of Curcumin and Paclitaxel by “Core-Shell” Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer
por: Zhao, Meng-Dan, et al.
Publicado: (2019)

MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
por: Yan, Jie, et al.
Publicado: (2021)

Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429
por: Guo, Qinglong, et al.
Publicado: (2018)

Aspirin reverses inflammatory suppression of chondrogenesis by stabilizing YAP
por: Wang, Xudong, et al.
Publicado: (2022)

Impeller meridional plane optimization of pump as turbine
por: Sen-chun, Miao, et al.
Publicado: (2019)

WISP2 promotes cell proliferation via targeting ERK and YAP in ovarian cancer cells
por: Shi, Zi-Qing, et al.
Publicado: (2020)

Integrated Analysis of Gene Expression Profiles Associated with Response of Platinum/Paclitaxel-Based Treatment in Epithelial Ovarian Cancer
por: Han, Yong, et al.
Publicado: (2012)

LINC01118 Modulates Paclitaxel Resistance of Epithelial Ovarian Cancer by Regulating miR-134/ABCC1
por: Shi, Cong, et al.
Publicado: (2018)

A case report for severe hand-foot skin reaction caused by chemotherapy with actinomycin D in a patient with oculocutaneous albinism
por: Yan, Shi-Jie, et al.
Publicado: (2019)

Treatment of liver metastases in patients with epithelial ovarian cancer
por: Deng, Hao, et al.
Publicado: (2021)

Efficacy of weekly paclitaxel for the treatment of advanced ovarian cancer: A protocol for systematic review and meta-analysis
por: Zhao, Dong-xu, et al.
Publicado: (2020)

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer
por: Silasi, Dan-Arin, et al.
Publicado: (2007)

Can proton pump inhibitors cause intestinal inflammation in children?
por: Kang, Ben
Publicado: (2019)

Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China
por: Luo, Hongli, et al.
Publicado: (2019)

Structure of the Dietzia Mrp complex reveals molecular mechanism of this giant bacterial sodium proton pump
por: Li, Bin, et al.
Publicado: (2020)

Silencing Snail Reverses Epithelial-Mesenchymal Transition and Increases Radiosensitivity in Hypopharyngeal Carcinoma
por: Wang, HaiYan, et al.
Publicado: (2020)

Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival
por: Sun, Fei, et al.
Publicado: (2015)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
por: Qin, Bao-Dong, et al.
Publicado: (2021)

The Involvement of the RhoA/ROCK Signaling Pathway in Hypersensitivity Reactions Induced by Paclitaxel Injection
por: Pan, Chen, et al.
Publicado: (2019)

Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition
por: Chen, Chen, et al.
Publicado: (2019)

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling
por: XIAO, JUAN, et al.
Publicado: (2015)

Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathway
por: Fu, Weiwei, et al.
Publicado: (2020)

Reduction of CA125 Levels During Neoadjuvant Chemotherapy Can Predict Cytoreduction to No Visible Residual Disease in Patients with Advanced Epithelial Ovarian Cancer, Primary Carcinoma of Fallopian tube and Peritoneal Carcinoma
por: Zeng, Jing, et al.
Publicado: (2016)

YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients
por: Xia, Yan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ujr2vlvphogs4b9brr489i3oua